The transcription factor GATA-3 is expressed and required for differentiation and function throughout the T lymphocyte lineage. Despite evidence it may also be expressed in multipotent hematopoietic stem cells (HSCs), any role for GATA-3 in these cells has remained unclear. Here we found GATA-3 was in the cytoplasm in quiescent long-term stem cells from steady-state bone marrow but relocated to the nucleus when HSCs cycled. Relocation depended on signaling via the mitogen-activated protein kinase p38 and was associated with a diminished capacity for long-term reconstitution after transfer into irradiated mice. Deletion of Gata3 enhanced the repopulating capacity and augmented the self-renewal of long-term HSCs in cell-autonomous fashion without affecting the cell cycle. Our observations position GATA-3 as a regulator of the balance between self-renewal and differentiation in HSCs that acts downstream of the p38 signaling pathway. npg
A r t i c l e s GATA-3 is a zinc-finger transcription factor that is essential for differentiation and function throughout the T lymphocyte hierarchy 1 . In common with many transcription factors, its localization between cytoplasm and nucleus is governed by modification of its classical nuclear-localization signal motif 2 . In human T lymphocytes, the GATA-3 nuclear-localization motif is phosphorylated at serine by the activated form of the mitogen-activated protein kinase p38 downstream of activation of the T cell antigen receptor, leading to binding of importin-α and carriage into the nucleus 3 . Beyond its expression in developing T cells, expression of Gata3 mRNA has also been reported further upstream in sorted populations enriched for mouse long-term multipotent hematopoietic stem cells (LT-HSCs) [4] [5] [6] . While the RNA evidence might indicate a function for GATA-3 in HSCs, it is paradoxical that deletion of Gata3 targeted to HSCs has not yielded a phenotype of hematopoietic deficiency beyond the T lymphocyte lineage [7] [8] [9] . The absence of an altered phenotype raises questions that remain outstanding, including whether Gata3 transcripts have been correctly attributed to LT-HSCs rather than to contaminating cell types in the impure HSCs fractions analyzed or whether Gata3 RNA is translated in HSCs into functional GATA-3 protein. Furthermore, as GATA-3 depends on upstream signaling for its activation 3 , it is not clear whether previous deletion studies adequately tested circumstances in which GATA-3 was in an active state.
HSCs are able to reconstitute all blood lineages from a single purified cell after transplantation into irradiated mice 6, 10 . Two distinct classes of HSCs have been identified on the basis of differences in biology and phenotype. LT-HSCs express the receptor SLAMF1 (CD150) 5, 6, 11 but not the integrin α 2 (CD49b) 6 and generate grafts that indefinitely sustain the output of myeloid, erythroid and lymphoid cells. They are deeply quiescent in the normal steady-state bone marrow, with intermitotic intervals estimated at 50-100 d, as determined by their rate of dilution of green fluorescent protein (GFP)-tagged histone H2B 12, 13 . Intermediate-term HSCs (IT-HSCs) do express α 2 integrin 6 , which allows them to be prospectively separated from LT-HSCs, are threefold more numerous than LT-HSCs 13, 6 and generate systemic grafts from single injected cells that sustain the production of myeloid and erythroid cells for 12 weeks before subsequent regression of the clones 5, 6, 14 . They are similarly quiescent in the normal steady state but reenter the cell cycle more frequently (every 10-20 d) than do LT-HSCs, as demonstrated by their more rapid rate of dilution of GFP-tagged histone H2B 12, 13 . Their greater abundance, their extensive proliferative capacity and their more frequent exit from quiescence indicate a quantitatively dominant role for IT-HSCs in maintaining blood-cell production in the steady state 15 . Gata3 transcripts are more abundant in α 2 integrinnegative fractions 6 , which suggests expression of Gata3 in LT-HSCs rather than IT-HSCs. Given the known involvement of GATA-3 in the differentiation of progenitor hierarchies in T lymphocyte and mammary luminal epithelial lineages, that observation raises the possibility that GATA-3 might be involved in specifying the sustained self-renewal property of LT-HSCs or the transition from LT-HSC to IT-HSC.
Here we report results that resolve the ambiguities in the earlier evidence and identify a previously unrecognized role for GATA-3 as an HSC-autonomous regulator of cell fate. We obtained direct proof of the expression of Gata3 mRNA and GATA-3 protein in LT-HSCs but not in more advanced HSCs. Furthermore, in LT-HSCs purified A r t i c l e s to functional homogeneity, we found that GATA-3 protein relocated from the cytoplasm to the nucleus in response to external signals, a change associated with both exit from quiescence and a reduction in the capacity for long-term reconstitution in irradiated hosts. Finally, we used conditional deletion of Gata3 in LT-HSCs to establish a causal link between GATA-3 activation and reduction in the longterm reconstitution ability and thus to demonstrate a gain in HSC self-renewal, without a change in cycling parameters, as the essential consequence of Gata3 deletion.
RESULTS
LT-HSCs express Gata3 RNA and GATA-3 protein The 'LSKRα 2 lo fraction' , sorted by low expression of lineage markers (Lin lo ), expression of the markers Sca-1 and c-Kit (LSK), low retention of the mitochondrial membrane-intercalating dye rhodamine 123 (Rho lo ) and low expression of α 2 integrin (α 2 lo ), contains LT-HSCs at 30% functional purity 6 . We confirmed by quantitative RT-PCR that Gata3 transcripts were 47-fold more abundant in that fraction than in the LSKRα 2 hi fraction, which consists entirely of IT-HSCs ( Supplementary Fig. 1 ). To link Gata3 expression more definitively to LT-HSCs, we took advantage of a mouse strain (Gata3 GFP/+ ) in which exon 4 of Gata3 is replaced with a cassette encoding enhanced GFP (eGFP) expressed from the endogenous Gata3 promoter 16 . We sorted Gata3 GFP/+ bone marrow cells into eGFP − , eGFP lo and eGFP hi fractions ( Fig. 1a) . Competitive erythroid-reconstitution assays 32 weeks in duration ( Fig. 1b) showed that long-term reconstituting activity (as well as phenotypic LT-HSCs; Supplementary Fig. 1 ) was present almost exclusively in the eGFP lo and eGFP hi fractions. In contrast, nearly all intermediate-term reconstituting activity at 8-16 weeks remained in the eGFP − fraction. These results indicated 'preferential' transcriptional activity of Gata3 in functionally defined LT-HSCs.
The lack of an altered phenotype resulting from deletion might be expected if Gata3 mRNA were not translated into a functional protein in HSCs. We therefore assessed GATA-3 expression by immunostaining. We detected GATA-3 protein in 30% of LSKRα 2 lo cells, which corresponds to the proportion of cells in this fraction able to generate long-term hematopoietic grafts 6 , but we did not detect GATA-3 protein in LSKRα 2 hi cells, which consist entirely of IT-HSCs ( Fig. 2a,b ). When we added SLAMF1 to the isolation strategy ( Fig. 2c) , 85% of LSKRα 2 lo SLAMF1 hi cells immunostained for GATA-3 ( Fig. 2d) . In erythroid-reconstitution assays assessed at 32 weeks, 50 LSKRα 2 lo SLAMF1 hi cells reproducibly competed 1:1 with 1 × 10 6 bone marrow cells ( Fig. 2e) , a competitor dose that should contain about 50 LT-HSCs 6 . The achievement of 50% donor reconstitution at 24-32 weeks indicated functional homogeneity of the LSKRα 2 lo SLAMF1 hi fraction. These observations showed direct correspondence between the proportion of cells that immunostained for GATA-3 protein and the extent of HSC purification and suggested that the LSKRα 2 lo SLAMF1 hi marker combination achieved the closest approach for the purification of functional long-term HSCs reported so far.
GATA-3 localization responds to cellular signaling
Having established the presence of GATA-3 protein in purified LT-HSCs, we sought to determine whether its activity or activation state would be responsive to upstream signaling. GATA-3 was in the cytoplasm in quiescent, freshly isolated LSKRα 2 lo cells ( Fig. 2a) . To assess the responsiveness of GATA-3 to cytokine signaling, we cultured LSKRα 2 lo cells with serum, the ligand for the stem-cell-factor receptor c-Kit, the ligand for the receptor tyrosine kinase Flt3, interleukin 11 (IL-11) and IL-7. Cultured cells began dividing by 40 h (data not shown), as expected 6 . GATA-3 was readily detectable in nuclei by 24 h and was mainly nuclear by 48 h (Fig. 3a-c) .
To determine whether entry of GATA-3 into the nucleus of LSKRα 2 lo cells might be controlled by p38, as it is in human T lymphocytes, we first investigated whether p38 was activated in cultured LSKRα 2 lo SLAMF1 hi cells. Activation of p38α, the dominant p38 isoform in hematopoietic cells, in cultured LSK cells has been described 17 . However, LSKRα 2 lo SLAMF1 hi cells represent less than 3% of LSK cells and therefore activation of p38 specifically in LT-HSCs expressing GATA-3 remained to be established. As assessed by immunofluorescence microscopy, the abundance of phosphorylated p38α was measurably greater after 15 min of exposure to medium containing serum and cytokines ( Fig. 3d) . To assess directly whether relocalization of GATA-3 to the nucleus depended on activation by p38, we cultured HSCs in the presence of specific inhibitors of the catalytic activity of p38α. We tested the following two agents: SB203580, a 'first-generation' pyrimidinyl imidazole inhibitor 18 , and SB239063, a 'second-generation' inhibitor of the same class having greater specificity for p38α than does SB203580, as well as higher potency 19 . Each significantly inhibited the localization of GATA-3 to the nucleus at a concentration of 10 µM ( Fig. 3e,f) , which is within the concentration range originally established for high p38α specificity 19, 20 . Inhibition at a concentration of 3 µM was greater with SB239063 than with SB203580 ( Fig. 3f ). Neither inhibitor affected subsequent cell growth in culture (data not shown). The observations showed translocation of GATA-3 protein to the nucleus in LT-HSCs after exposure to cytokines and activation from quiescence, indicated that activated p38α was a required signal for the activation of GATA-3 and its entry into the nucleus and suggested a function for GATA-3 in cycling LT-HSCs rather than quiescent LT-HSCs. Those interferons are typically induced by administration of the synthetic RNA duplex poly(I:C), which signals through Toll-like receptor 3 to induce many downstream effects in addition to the expression of type I interferons 21 . Because of the likelihood that poly(I:C) administration might itself affect HSCs independently of Gata3 deletion, 
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A r t i c l e s we first characterized its effects on HSCs in wild-type mice. Poly(I:C) is known to induce HSC cycling in vivo, with a single injection having maximal effect at 48 h, followed by return to quiescence by 4 d (ref. 22 ). We analyzed the in vivo cell-cycle response of LSKα 2 lo SLAMF1 hi cells 1 d and 10 d after three successive injections of poly(I:C). We omitted rhodamine 123 from the cell-sorting protocol because the Rho lo characteristic is selective for quiescent cells 23 . We stained freshly isolated cells intracellularly with the proliferation marker Ki67 and the nuclear dye Hoechst 33342 ( Fig. 4a) . Most (81%) LSKα 2 lo SLAMF1 hi cells were in the G1 or G2-M phase of the cell cycle 1 d after treatment with poly(I:C) and returned to quiescence by 10 d. We also examined GATA-3 localization in these cells on days 1 and 10 and 5 months after injection of poly(I:C) ( Fig. 4b) . GATA-3 was still mostly nuclear at 10 d, but at 5 months after treatment, a substantial proportion of GATA-3 was again in the cytoplasm (Fig. 4b) . Thus, as observed in vitro, relocalization of GATA-3 to the nucleus of HSCs also occurred in vivo after treatment that induced HSC cycling and was followed by delayed return to the cytoplasm after reversion of HSCs to quiescence.
We next investigated whether GATA-3 that had relocated to the nucleus might affect the regenerative activity of LT-HSCs. We treated wild-type C57BL/6J-Ly5.2-Gpi1 b/b mice (C57BL/6J Ly5.2 + mice that express the 'b' isoform of the universally expressed enzyme Gpi1 (glucose phosphate isomerase 1)) with poly(I:C), isolated LSKRα 2 lo cells from the bone marrow 10 d or 5 months later and transplanted the cells into irradiated C57BL/6J-Ly5.1-Gpi1 a/a hosts (C57BL/6J Ly5.1 + mice that express the 'a' isoform of Gpi1) in competition with unfractionated bone marrow cells of the wild-type recipient genotype. At 8 weeks after transplantation, cells obtained at either time point after treatment with poly(I:C) achieved erythroid reconstitution similar to that of cells from untreated mice ( Fig. 4c ), suggesting that IT-HSCs (normally the majority HSC type in the LSKRα 2 lo fraction 6 ) were not affected. However, at 24-32 weeks after transplantation, LSKRα 2 lo cells that had been treated with poly(I:C) 10 d before transplantation, when the cells had returned to quiescence but in which GATA-3 was still intranuclear, yielded a markedly lower level of erythroid reconstitution (Fig. 4c) , which represented a sixfold reduction in the number of long-term reconstituting cells by treatment with poly(I:C).
That result was concordant with published reports of a depleting effect of poly(I:C) on the long-term reconstituting potential of bone marrow cells 22, 24 . In contrast, we achieved robust reconstitution with control cells not treated with poly(I:C) and by LSKRα 2 lo cells treated with poly(I:C) 5 months before to transplantation ( Fig. 4c) , in which GATA-3 was again in the cytoplasm (Fig. 4b) . These observations indicated that HSCs with nuclear GATA-3 had diminished long-term reconstituting capacity, which suggested a correlation between the regenerative performance of LT-HSCs and localization of GATA-3, whereas the regenerative activity of functional IT-HSCs, which lack GATA-3, was near control levels after treatment with poly(I:C).
Little effect of Gata3 deletion on steady-state hematopoiesis
To achieve deletion of Gata3 in hematopoietic cells, we used a mouse strain (Gata3 fl/fl ) in which the fourth exon of Gata3 (which encodes the first zinc finger) is flanked by loxP 25 . We crossed Gata3 fl/fl mice with Mx1-Cre mice to yield Gata3 fl/fl -Mx1-Cre mice. Induction of Cre recombinase in these mice yields a truncated Gata3 transcript predicted to splice out of frame to exon 5 (which encodes the second zinc finger), which translates into an inactive protein lacking both zinc fingers 25 . We routinely used as 'undeleted' controls Gata3 fl/fl mice given the same poly(I:C) treatment that the Gata3 fl/fl -Mx1-Cre mice received.
We treated Gata3 fl/fl -Mx1-Cre mice with poly(I:C) to induce deletion of Gata3 and examined blood cells and bone marrow precursor populations 3-9 months later. We found little effect of Gata3 excision on the proportion (Fig. 5a ) or absolute number (data not shown) of circulating myeloid or lymphoid cells or on the number of LSKRα 2 lo SLAMF1 hi and LSKRα 2 hi SLAMF1 lo HSCs in the bone marrow. Because a published report has suggested that Gata3-deficient HSCs are more quiescent in steady-state conditions than are intact HSCs 9 , we also assessed the cell-cycle status of LSKα 2 lo SLAMF1 hi cells by intracellular staining with Ki67 and Hoechst 33342 in the bone marrow of Gata3 fl/fl -Mx1-Cre and Gata3 fl/fl mice 3 months after treatment with poly(I:C). We found that 85% of LSKα 2 lo SLAMF1 hi cells were quiescent, with no significant difference between 'undeleted' Gata3 fl/fl control mice and Gata3 fl/fl -Mx1-Cre mice in the distribution of staining A r t i c l e s with Ki67 and Hoechst 33342 ( Fig. 5b) . We also assessed the cellcycle response of Gata3-deficient LSKα 2 lo SLAMF1 hi cells to a second round of treatment with poly(I:C) and found they entered the cell cycle to a degree similar to that of Gata3-intact control cells (Fig. 5b) . The lack of an apparent effect of Gata3 deletion on the steady-state maintenance of bone marrow confirmed a published report 8 and was consistent with the localization of GATA-3 in the cytoplasm in quiescent LT-HSCs. Diagnostic PCR of total bone marrow cells and circulating myeloid cells at various times after three successive injections of poly(I:C) consistently indicated a minimum 97% efficiency of Gata3 excision (Fig. 5c) . Additionally, in clones grown in culture from individual LSKR cells obtained 10 d after treatment with poly(I:C), Gata3 excision was complete in 99 of 101 the clones examined. These results showed that Gata3 deficiency had little effect on blood cell production or LT-HSC maintenance in steady-state conditions in which LT-HSCs were quiescent and GATA-3 was mainly in the cytoplasm.
Gata3 excision protects LT-HSCs from depletion by poly(I:C)
We next looked for possible consequences of Gata3 deficiency in conditions in which GATA-3 would be intranuclear. We obtained unfractionated bone marrow cells (1 × 10 6 ) from Gata3 fl/fl -Mx1-Cre or Gata3 fl/fl mice 10 d after poly(I:C) treatment, when GATA-3 was mainly nuclear (Fig. 4b) , and injected those cells, in competition with untreated wild-type bone marrow cells (1 × 10 6 ), into irradiated recipients. We monitored hematopoietic reconstitution in primary transplant recipients at 8, 16, 24 and 32 weeks as a measure of the long-term reconstitution potential of transferred cells. While wildtype bone marrow treated with poly(I:C) was depleted of long-term reconstituting activity, we found no such defect for poly(I:C)-treated Gata3 fl/fl -Mx1-Cre bone marrow, which robustly sustained erythroid, myeloid and B lymphocytic lineages in primary recipients for 32 weeks (Fig. 6a) , matching or exceeding the regenerative activity of the coinjected untreated wild-type competitor cells. As expected, the regeneration of T lymphocytes by poly(I:C)-treated Gata3 fl/fl -Mx1-Cre bone marrow was weak relative to the reconstitution of myeloid and B lymphocytes (Fig. 6a) . These results showed that poly(I:C)-induced translocation of GATA-3 to the nucleus impaired the long-term regenerative capacity of bone marrow LT-HSCs and that deletion of Gata3 reversed that effect.
Gata-3 deletion enhances numerical expansion of LT-HSCs in vivo
Because GATA-3 relocated to the nucleus when LT-HSCs were induced to cycle, we next sought to determine whether functional consequences of Gata3 deletion might be apparent in LT-HSCs after transfer into irradiated mice, in which they enter active cell cycle and have been shown to expand in number by a factor of 10 after transplantation of 1 × 10 6 bone marrow cells 26, 27 . We treated Gata3 fl/fl -Mx1-Cre mice with poly(I:C) to delete Gata3, obtained bone marrow 10 d later and measured erythroid regenerative activity competitively in primary recipient mice by coinjection of 1 × 10 6 unfractionated cells with 1 × 10 6 bone marrow cells from untreated wild-type mice of the recipient genotype. We measured the proportion of donor and competitor erythrocytes in blood at 24 weeks by quantifying isoforms of Gpi1 in an initial Gpi1 assay, from which we estimated the number of LT-HSCs with Gata3 deletion that were initially injected, as described 6 .
We obtained unfractionated bone marrow at 24 weeks from primary recipients and transplanted that into irradiated secondary recipients. After a further 24 weeks, we again determined the proportion of donor and competitor erythrocytes in a second Gpi1 assay. We then injected unfractionated bone marrow cells from secondary recipients in varying numbers into tertiary recipients to count LT-HSCs that originated from cells in which Gata3 was deleted and from wild-type competitor cells by limiting-dilution analysis of erythroid-reconstituting activity at 20 weeks. We combined the results of the second Gpi1 assay, the limiting-dilution assay and the historically determined content of 1 × 10 6 normal competitors as described 6 to determine the number of LT-HSCs initially injected into secondary recipients and the number recovered from them. We used those numbers to compute the net numerical expansion of LT-HSCs that occurred in primary and secondary recipients (Fig. 6b) . Untreated wild-type competitor LT-HSCs expanded in number in primary and secondary recipients by 10-and 7.5-fold during the primary and secondary reconstitutions, A r t i c l e s respectively, to achieve a cumulative numerical expansion of 75-fold (Fig. 6b) . In contrast, Gata3-deficient LT-HSCs expanded in number by 20-fold during regeneration in primary recipient mice and a further 13-fold in secondary recipients to achieve a cumulative 260-fold increase over the number of initially transferred LT-HSCs (Fig. 6b) . These results showed that Gata3-deficient LT-HSCs expanded in number to a greater extent during sequential regeneration in vivo than did wild-type control HSCs, suggesting that GATA-3 must restrain the extent to which normal LT-HSCs expand in number during regeneration of the bone marrow.
Effect of GATA-3 on HSC self-renewal is HSC autonomous
To ensure that the regenerative advantage of Gata3-deficient HSCs was HSC autonomous and was not due to systemic effects of Gata3 deletion in poly(I:C)-treated Gata3 fl/fl -Mx1-Cre mice, we transplanted 0.5 × 10 6 unfractionated bone marrow cells from Gata3 fl/fl -Mx1-Cre mice or Gata3 fl/fl control mice, together with 1 × 10 6 wild-type competitor bone marrow cells, into irradiated wild-type mice and induced Gata3 deletion by treating the recipient mice with poly(I:C) 8 weeks after transfer. In this experimental strategy, Gata3 would be deleted only in the Gata3 fl/fl -Mx1-Cre cells. At 24 weeks after reconstitution, we obtained unfractionated bone marrow cells from the mixed chimeras and injected them into secondary irradiated hosts, then quantified the extent of the increase in LT-HSC number from cells in which Gata3 was deleted and from control cells in which it was not deleted. Gata3-deficient LT-HSCs again had a substantial regenerative advantage over wild-type cells (Fig. 6c) . These results suggested a cell-autonomous effect of GATA-3 on the regenerative advantage of HSCs that was independent of the environment in which Gata3 deletion was induced.
Gata3 excision protects LT-HSCs from depletion in culture
We also assessed the functional consequences of Gata3 deletion in cultured LT-HSCs, in which GATA-3 also relocated to the nucleus (Fig. 3) . We treated Gata3 fl/fl -Mx1-Cre mice with poly(I:C) 3-5 months before cell isolation, then purified quiescent LSKRα 2 lo or LSKRα2 lo SLAMF1 hi cells from those mice or from wild-type untreated mice, and then cultured the cells for 7 d at a density of one cell per microwell. During culture, cloning efficiency (90-95%), latency to onset of growth 6 (data not shown), cell number and subsequent division rate (Fig. 6d) were not significantly affected by Gata3 deletion relative to the results obtained for wild-type control cells. Purified wild-type LT-HSCs normally maintain their in vivo competitive reconstituting activity for the first 4 d in culture. Activity decreased steeply thereafter, and we recovered little or no long-term activity by 7 d (Fig. 6e) . In contrast, Gata3-deficient HSCs maintained their long-term competitive reconstituting activity throughout the 7 d of culture (Fig. 6e) . These results added to the evidence that activated GATA-3 exerted a negative regulatory effect on the long-term regenerative capacity of LT-HSCs in a way that probably did not involve changes in cell cycling.
DISCUSSION
Published work has suggested little effect of GATA-3 on steady-state hematopoiesis beyond its role in T lymphocyte production and function 7-9 . Here we have reported observations that explain those results and define a strong function for GATA-3 in LT-HSCs. The quiescence of LT-HSCs and sequestration of GATA-3 to the cytoplasm in steadystate bone marrow provide a plausible basis for the observations here and before demonstrating little effect of Gata3 deletion on steadystate hematopoiesis: most GATA-3 protein was inactive in quiescent LT-HSCs and its deletion should not influence their activity, while IT-HSCs that do the bulk of bone marrow maintenance did not express Gata3. Deficiency in Gata3 in regenerative contexts did not lead to loss of function, which the previously published studies were configured to detect, but instead led to a gain in the extent of self-renewal, whose detection requires suitably configured quantitative assays. In every context tested in which GATA-3 was expected to be activated (growth in culture, response to poly(I:C) in vivo and regeneration after transfer into irradiated mice), its absence led to an enhancement in the number of LT-HSCs detected in functional assays. Moreover, the experiments measuring numerical expansion in vivo showed that 
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A r t i c l e s the effects of Gata3 deletion were LT-HSC autonomous. Thus, deletion of Gata3 consistently led to a gain in self-renewal during LT-HSC proliferation, which suggested a role for GATA-3 in restraining selfrenewal in proliferating LT-HSCs. Although our findings have confirmed a lack of effect of Gata3 deletion on steady state bone marrow function, as documented before 8 , the substantial enhancement of LT-HSC regeneration documented here in irradiated hosts was not apparent in that previous study 8 . Differences in Gata3-deletion strategies could account for this discrepancy. That previous study 8 used Cre recombinase expressed from the hematopoietic compartment-specific gene encoding Vav to achieve Gata3 excision at the first emergence of HSCs from hemogenic endothelium in the embryo. It is possible that homeostatic adjustments in the expression of compensatory genes were more complete in that model than in our Mx1-Cre model, in which Gata3 was deleted in adult life in already formed LT-HSCs.
The means by which GATA-3 restrains self-renewal remain to be determined. One possible mechanism would be restraint of proliferation. Such an effect would be contrary to published results suggesting that GATA-3 actually promotes the cycling of LT-HSCs 9 . However, we did not observe any effects of Gata3 deletion on the cell cycle either in vitro or in vivo. Promotion of apoptosis in cycling cells is another formal possibility, but this was similarly not supported by our observations of kinetics in culture. An alternative mechanism would be promotion of the differentiation of LT-HSCs toward IT-HSCs, a step that we found also involved sharp downregulation of Gata3 expression. Such a role would place GATA-3 as a regulator of the balance between self-renewal and differentiation in LT-HSCs, mediating their reprogramming from multipotent cells with unlimited regenerative lifetime to multipotent IT-HSCs with a 3-month regenerative potential.
An analogous 'pro-differentiation' role for GATA-3 has been shown in luminal breast epithelial progenitor cells, in which GATA-3 is required for differentiation into a mature ductal epithelial phenotype and in which deletion of GATA-3 results in the numerical expansion of undifferentiated precursors 28 . Although in luminal stem cells, the requirement for GATA-3 in differentiation seems to be absolute, LT-HSCs are still able to differentiate in its absence, which suggests redundancy in elements that control the differentiation process 8 . In the mammary system, GATA-3 acts together with the transcription factor Foxa1 as a 'pioneer' factor [29] [30] [31] [32] involved in nucleating a remodeling complex at heterochromatic enhancer regions that are targets of the estrogen receptor, leading to the opening and epigenetic marking of sites for active transcription. A similar role in LT-HSCs could provide a mechanism for the stable transformation of cellular identity to the IT-HSC stage.
If GATA-3 suppresses self-renewal in proliferating LT-HSCs, an apparent paradox arises: when bone marrow is transplanted into irradiated recipient mice, in the weeks after the transplant, the number of LT-HSCs normally increases tenfold over the number injected 10, 26, 27 . LT-HSCs are induced to proliferate in the ablated-bone-marrow milieu 33, 34 , and GATA-3 might be expected to be activated and relocate to the nucleus. If so, how would a net increase in LT-HSCs occur?
We were unable to assess the extent of entry of GATA-3 in the nucleus by immunofluorescence microscopy in this setting because marker sets that allow the purification of quiescent LT-HSCs to homogeneity do not yield sufficient functional purity when applied to regenerating bone marrow 35 . Conceivably, the degree of activation of GATA-3 and its relocation to the nucleus in physiologically regenerating bone marrow could be less than we observed in culture or in vivo consequent to treatment with poly(I:C). Positive signals may also be available in regenerating bone marrow that partially balance the negative action of GATA-3. Nevertheless, deletion of Gata3 augmented the numerical expansion of LT-HSCs injected, which suggested that in physiologically regenerating bone marrow, GATA-3 is activated at a level sufficient to constrain, but not to abolish, increases in LT-HSC numbers.
Translocation of GATA-3 to the nucleus has been shown in human T lymphocytes to depend on phosphorylation of serine at the nuclear-localization signal sequence via direct catalysis by p38 and consequent interaction with importin-α 3 . To investigate a corresponding dependence on p38α in LT-HSCs, we used two selective inhibitors of p38α whose few known off-target kinases are affected only at concentrations one to two orders of magnitude higher than those used here 19, 20, 36, 37 . Our results obtained with mouse LT-HSCs have confirmed in a new cellular context that activation of GATA-3 depends on activated p38. We also confirmed that p38α is indeed activated in cultured LT-HSCs. Activation of p38α has also been documented downstream of Toll-like receptor 3 responding to poly(I:C) in dendritic cells and natural killer cells 38, 39 , as well as to c-Kit 40 , tumor-necrosis factor and transforming growth factor-β 41 and signaling via reactive oxygen species 42 in a variety of hematopoietic cells. Our identification of GATA-3 as a negative agonist in LT-HSCs responding to the activation state of the p38 signaling pathway implicates it as a potentially critical mediator of the LT-HSCdepleting effects of inflammatory cytokines and reactive oxygen species in the earliest HSCs. Those effects should be mitigated by inhibition of p38 signaling, and enhanced preservation of LT-HSCs cultured in the presence of p38α inhibitors has indeed been observed 17 . Our findings have collectively identified a physiological mechanism that constrains the capacity of bone marrow stem cells to engraft long term and have shown that interference with that mechanism can lead to enhanced self-renewal of LT-HSCs. Our observations have potential therapeutic implications, as augmenting the number of long-term stem cells either in culture or in vivo could enhance the efficacy, safety and range of applicability of the clinical transplantation of HSCs.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
ONLINE METHODS
Mice. Gata3 GFP/+ and Gata3 fl/fl mice were maintained by M.B. 16, 25 and were backcrossed onto C57BL/6J mice for five or more generations before use. The genotyping primers for Gata3 GFP/+ mice were as follows: 5′-CGCCGCCGGGATCACTCTCG-3′ and 5′-GATCCAGACATGAT AAGATACA-3′. Gata3 fl/fl mice were bred with C57BL/6J-Mx1-cre deleter mice (The Jackson Laboratory). The genotyping primers for Cre were 5′-GCGGTCTGGCAGTAAAAACTATC-3′ and 5′-GTGAAACAGCA TTGC TGTCACTT-3′, and for loxP-flanked and wild-type Gata3 alleles were 5′-GTCAGGGCACTAAGGGTTGTT-3′ and 5′-TGGTAGAGT CCGCAGGCATTG-3′. Excision of the Gata3 fl allele was detected with primers 5′-GTCAGGGCACTAAGGGTTGTT-3′ and 5′-TATCAGCGGTT CATCTACAGC-3′.
The genotypes of bone marrow donors were C57BL/6J-Ly5 For excision of Gata3 in Gata3 fl/fl -Mx1-Cre mice, 300 µg high-molecularweight poly(I:C) (InvivoGen) in isotonic saline was administered intraperitoneally on alternate days for a total of three injections. Mice did not develop adverse effects after treatment.
Cell culture. Cells were incubated at 37 °C in 5% CO 2 in U-bottomed microtiter wells (Nunclon) in 100 µl IMDM containing 7.5 × 10 −5 M α-thioglycerol, 4% FBS, 0.1% BSA, 5 µg/ml transferrin, 5 µg/ml insulin, 50 ng/ml c-Kit ligand, 50 ng/ml Flt3 ligand, 10 ng/ml IL-11 and IL-7, as 0.25% conditioned medium of transduced producer cells, all as described 6, 10 . For analysis of the growth kinetics of single cells, sorted cells were plated at limiting dilution and wells containing exactly one cell each were identified visually after 18 h of culture. Reconstitution assays. Cells for which HSC activity was to be measured by injection into irradiated hosts differed from the host cells by expression of distinguishable isoforms of the Ly5 (CD45) surface antigen that marks myeloid and lymphoid cells and by isoforms of Gpi1, which was used to distinguish circulating erythrocytes. For quantitative competitive assays, unseparated C57BL/6J-Ly5.2-Gpi1 b/b bone marrow cells or 30 to 100 purified HSCs were injected together with 0.5 × 10 6 to 1 × 10 6 C57BL/6J-Ly5.1-Gpi1 a/a competitor bone marrow cells into irradiated C57BL/6J-Ly5.1-Gpi1 a/a recipient mice (9 Gy; 137 Cs). Limiting-dilution assays were done in sublethally irradiated C57BL/6J-Ly5.1-Kit W−41J/W−41J -Gpi1 a/a host mice (4 Gy; 137 Cs). The ratio [(proportion donor)/(1 − proportion donor)] is linearly related to the number of HSCs injected in competitive assays 43 . This value was combined with the known frequency of LT-HSCs in normal competitor bone marrow (1:18,200) 6 to derive from competitive assay outcomes (typically erythroid-reconstitution values) an estimate of the absolute numbers of HSCs in the assayed samples as described 6, 27 .
Inhibitors
For the experiment in Figure 6b , bone marrow cells in which Gata3 was deleted (1 × 10 6 ) were transplanted into irradiated primary recipients together with 'normal' competitor cells (1 × 10 6 ). The proportion of donor and competitor erythrocytes was measured in blood at 24 weeks, followed by transplantation of 1.5 × 10 7 primary bone marrow cells without fresh competitors into irradiated secondary recipients. The proportion of donor and competitor erythrocytes was measured at 24 weeks. Erythroid-reconstituting cells in bone marrow from secondary recipients were quantified by limiting-dilution analysis. Irradiated B6-Kit W−41J/W−41J mice (4 Gy) were given transplantation of 2 × 10 5 , 6 × 10 5 or 8 × 10 5 cells per mouse, followed by quantification of mice positive for erythroid reconstitution at 20 weeks. Mice had either undetectable reconstitution or at least 15% donor erythrocytes.
For the experiment in Figure 6c , Gata3 fl/fl or Gata3 fl/fl -Mx1-Cre l bone marrow cells (5 × 10 5 ) were injected together with 'normal' competitor cells (1 × 10 6 ) into irradiated wild type recipient mice. Host mice were treated with poly(I:C) 8 weeks later. The proportion of donor erythrocytes in blood was measured at 24 weeks and was used to estimate the number of LT-HSCs originally injected. Host bone marrow cells (1.5 × 10 7 ) were subsequently transferred into irradiated recipients and the proportion of donor erythrocytes was determined after 20 weeks. Those values were used to estimate the number of LT-HSCs regenerated in the primary recipients. Results are presented as expansion in LT-HSC numbers calculated to have occurred in the primary recipients.
For the experiment in Figure 6d , bone marrow from Gata3 fl/fl -Mx1-Cre and control Gata3 fl/fl mice was analyzed 2-3 months after treatment with poly(I:C). Single LSKRα 2 lo or LSKRα 2 lo SLAMF1 hi cells were cultured in microwells with serum and cytokines, and the number of cells per well was recorded every 4-8 h.
For the experiment in Figure 6e , Gata3 fl/fl -Mx1-Cre and control Gata3 fl/fl mice were killed 3-5 months after treatment with poly(I:C). LSKRα 2 lo SLAMF1 hi cells obtained from those mice were injected together with competitor cells (0.5 × 10 6 ) of the host genotype into irradiated recipient for analysis of longterm reconstituting activity, and some were also cultured at a density of one cell per well in 100 µl medium containing serum and cytokines. After 7 d of culture, all cells harvested from 25 wells were injected together with competitor cells (0.5 × 10 6 ) into each irradiated recipient. Erythroid reconstitution in the recipients was measured at 24 weeks.
Detection of donor erythrocytes and myeloid and lymphoid cells.
Erythrocyte Gpi1 isoforms were resolved by flat-bed electrophoresis through Super Sepraphore membranes (cellulose acetate on mylar; VWR/Pall) and Gpi1 bands were quantified as described 6 . For leukocytes, erythrocytes were lysed in NH 4 Cl and Fc receptors were blocked with antibody to CD16/32 (anti-CD16/32; 93), followed by reaction with fluorochrome-conjugated anti-Ly5.1 (A20), anti-Ly5.2 (104), anti-B220 (RA36B2), anti-CD11b (M1/70), anti-Ly6Gr1 (RB6-8C5) and anti-TCRβ (H57-597; all antibodies from eBioscience). Labeled cells were analyzed by flow cytometry (LSR II; Becton-Dickinson). The proportion of donor cells is presented as proportion of donor cells in the relevant lineage.
Purification of HSCs. Femoral and tibial bone marrow cells were treated with NH 4 Cl for lysis of red blood cells, then were stained with rhodamine 123 (Eastman Kodak), destained, incubated for 5 min with Fc receptorblocking antibody (anti-CD16/32; 93) and then incubated for 30 min at 4 °C with phycoerythrin-indodicarbocyanine-conjugated anti-B220 (RA3-6B2) and anti-CD3 (145-2C11; all antibodies from eBioscience) as described 6 . Washed cells were separated on a FACSAria (BD) and the Rho lo B220 − CD3 − fraction was collected. Recovered cells were labeled for 30 min with fluorochrome-conjugated phycoerythin-anti-CD49b (HMα2; BD Biosciences), phycoerythrin-indotricarbocyanine-anti-c-Kit (2B8; eBioscience) and allophycocyanin-anti-Sca-1 (D7; eBioscience), then were washed and sorted as LSKRα 2 lo and LSKRα 2 hi cells. For isolation with the markers α 2 integrin and CD150, cells were stained with rhodamine 123, and destained then populations were depleted of cells positive for lineage markers (CD5, B220, CD11b, Gr-1, neutrophil 7/4 antigen and Ter-119) through the use of magnetic beads and an autoMACS separator (Miltenyi Biotec). Samples that had undergone that depletion were then incubated with Fc receptor-blocking antibody, then stained for 30 min with phycoerythrin-indodicarbocyanine-anti-streptavidin (15-4317-82; eBioscience), phycoerythrin-indodicarbocyanine-anti-CD3 (145-2C11; eBioscience), phycoerythrin-indotricarbocyanine-anti-c-Kit, allophycocyanin-anti-Sca-1, Pacific blue-anti-CD150 (TC15-12F12.2; BioLegend) and phycoerythrin-anti-CD49b, and then were washed and sorted.
Transcript expression in purified cells. Globally amplified cDNA from LSKRα 2 lo and LSKRα 2 hi cells has been described 6 . The cDNA from the erythromyeloid hierarchy has been described 44, 45 . RNA from purified stages in the B lymphocyte hierarchy 46 and T lymphocyte hierarchy 47 was globally amplified as described 48 . PCR primers targeting sequence within a 300-base npg
